Background: Exchange transfusion (ET) is a high-risk procedure. The type and rate of complications in neonatal red cell alloimmune hemolytic disease exclusively are not clear. Objectives: Our aim was to study the type and rate of complications associated with ET in a large series of neonates with hemolytic disease of the fetus and newborn (HDFN) due to red cell alloimmunization. Methods: All neonates with HDFN due to red cell alloimmunization admitted to our center between January 2001 and June 2011 were eligible for this study. We recorded the number and rate of complications during admission in the group of neonates treated with ET (ET group) and not treated with ET (no-ET group). Multivariate logistic regression analysis was performed to measure the independent risk of complications of ET treatment. Results: A total of 347 infants with red cell alloimmune hemolytic disease were included; 39% (134/347) were treated with at least one ET (ET group), and 61% (213/347) did not require ET (no-ET group). Comparison between the ET group and no-ET group showed that ET treatment was independently associated with proven sepsis [8 vs. 1%, respectively; odds ratio (OR) 8.3, 95% confidence interval (CI) 1.7–40.3; p = 0.009], leukocytopenia (88 vs. 23%, respectively; OR 36.0, 95% CI 17.5–73.8; p < 0.001), severe thrombocytopenia (platelet count <50 × 109/l; 63 vs. 8%, respectively; OR 31.4, 95% CI 14.0–70.4; p < 0.001), hypocalcemia (22 vs. 1%, respectively; OR 27.4, 95% CI 5.9–126.8; p < 0.001) and hypernatremia (8 vs. 0%, respectively; p < 0.001). There were no neonatal deaths in the ET group. Conclusion: ET in neonates with HDFN is associated with an increased risk of sepsis, leukocytopenia, thrombocytopenia, hypocalcemia and hypernatremia.

Keywords:
Exchange transfusion, Hemolytic disease of the fetus and newborn, Adverse effects, Neonatal morbidity
1.
Diamond LK, Allen FH Jr, Thomas WO Jr: Erythroblastosis fetalis. VII. Treatment with exchange transfusion. N Engl J Med 1951;244:39–49.
2.
Badiee Z: Exchange transfusion in neonatal hyperbilirubinaemia: experience in Isfahan, Iran. Singapore Med J 2007;48:421–423.
3.
Davutoglu M, Garipardic M, Guler E, Karabiber H, Erhan D: The etiology of severe neonatal hyperbilirubinemia and complications of exchange transfusion. Turk J Pediatr 2010;52:163–166.
4.
Hosseinpour SS, Gharehbaghi MM: Exchange transfusion in severe hyperbilirubinemia: an experience in northwest Iran. Turk J Pediatr 2010;52:367–371.
5.
Ip S, Chung M, Kulig J, O’Brien R, Sege R, Glicken S, et al: An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 2004;114:e130–e153.
6.
Jackson JC: Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics 1997;99:E7.
7.
Keenan WJ, Novak KK, Sutherland JM, Bryla DA, Fetterly KL: Morbidity and mortality associated with exchange transfusion. Pediatrics 1985;75:417–421.
8.
Patra K, Storfer-Isser A, Siner B, Moore J, Hack M: Adverse events associated with neonatal exchange transfusion in the 1990s. J Pediatr 2004;144:626–631.
9.
Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG: A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics 2007;120:27–32.
10.
Rath ME, Smits-Wintjens VE, Lindenburg I, Brand A, Oepkes D, Walther FJ, et al: Top-up transfusions in neonates with Rh hemolytic disease in relation to exchange transfusions. Vox Sang 2010;99:65–70.
11.
Rath ME, Smits-Wintjens VE, Lindenburg IT, Brand A, Van Kamp IL, Oepkes D, et al: Exchange transfusions and top-up transfusions in neonates with Kell haemolytic disease compared to Rh D haemolytic disease. Vox Sang 2011;100:312–316.
12.
De Boer I, Zeestraten EC, Lopriore E, Van K, I, Kanhai HH, Walther FJ: Pediatric outcome in Rhesus hemolytic disease treated with and without intrauterine transfusion. Am J Obstet Gynecol 2008;198:54.e1–54.e4.
13.
Smits-Wintjens VE, Walther FJ, Rath ME, Lindenburg IT, te Pas AB, Kramer CM, et al: Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics 2011;127:680–686.
14.
Rath ME, Smits-Wintjens VE, Oepkes D, van Zwet EW, Van Kamp IL, Brand A, et al: Thrombocytopenia at birth in neonates with red cell alloimmune haemolytic disease. Vox Sang 2012;102:228–233.
15.
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297–316.
16.
Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al: Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978;187:1–7.
17.
Volpe JJ: Intracranial hemorrhage: germinal matrix-intraventricular hemorrhage of the premature infant; in Volpe JJ (ed): Neurology of the Newborn. Philadelphia, Saunders, 2001, pp 428–493.
18.
Smits-Wintjens VE, Steggerda SJ, Oepkes D, Van Kamp IL, Kramer CM, Walther FJ, et al: Bacillus cereus cerebral abscesses in a term neonate with rhesus hemolytic disease treated with exchange transfusion. J Pediatr Inf Dis 2010;5:277–280.
19.
Maisels MJ, Watchko JF: Treatment of jaundice in low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2003;88:F459–F463.
20.
Inglis GD, Davies MW: Prophylactic antibiotics to reduce morbidity and mortality in neonates with umbilical venous catheters. Cochrane Database Syst Rev 2005;(4): CD005251.
21.
Fergusson D, Hebert PC, Barrington KJ, Shapiro SH: Effectiveness of WBC reduction in neonates: what is the evidence of benefit? Transfusion 2002;42:159–165.
22.
Xanthou M, Nicolopoulos D, Gizas A, Matsaniotis N: The response of leukocytes in the peripheral blood during and following exchange transfusion in the newborn. Pediatrics 1973;51:570–574.
23.
Rath ME, Smits-Wintjens VE, Walther FJ, Lopriore E: Hematological morbidity and management in neonates with hemolytic disease due to red cell alloimmunization. Early Hum Dev 2011;87:583–588.
24.
Blanco E, Johnston DL: Neutropenia in infants with hemolytic disease of the newborn. Pediatr Blood Cancer 2012;58:950–952.
25.
Williams S, Chan AK: Neonatal portal vein thrombosis: diagnosis and management. Semin Fetal Neonatal Med 2011;16:329–339.
26.
Samsom JF, Groenendijk MG, van der Lei J, Okken A: Exchange transfusion in the neonate, a comparison between citrate-, heparinized- and reconstituted whole blood. Eur J Haematol 1991;47:153–154.
27.
Saade GR, Moise KJ Jr, Copel JA, Belfort MA, Carpenter RJ Jr: Fetal platelet counts correlate with the severity of the anemia in red-cell alloimmunization. Obstet Gynecol 1993;82:987–991.
28.
Van den Akker ES, de Haan TR, Lopriore E, Brand A, Kanhai HH, Oepkes D: Severe fetal thrombocytopenia in Rhesus D alloimmunized pregnancies. Am J Obstet Gynecol 2008;199:387–384.
29.
Maisels MJ, Li TK, Piechocki JT, Werthman MW: The effect of exchange transfusion on serum ionized calcium. Pediatrics 1974;53:683–686.
30.
Doyle PE, Eidelman AI, Lee K, Daum C, Gartner LM: Exchange transfusion and hypernatremia: possible role in intracranial hemorrhage in very-low-birth-weight infants. J Pediatr 1978;92:848–849.
31.
Steele AM, Brown DL, Lipsitz PJ: Relationship of exchange transfusion to hypernatremia. J Pediatr 1979;94:168–169.
32.
Smits-Wintjens VEHJ, Walther FJ, Lopriore E: Rhesus hemolytic disease of the newborn: postnatal management, associated morbidity and long-term outcome. Semin Fetal Neonatal Med 2008;13:265–271.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.